Partnership Aimed to Improve CNS Drug Development
A new collaboration between Cumulus Neuroscience and Transpharmation could help better translate preclinical findings to human clinical trials.
Updated on Oct. 14, 2026 in Alzheimer’s
Live Poll
Do you trust that strategic partnerships between research firms improve new medical treatment outcomes?
Cumulus Neuroscience and Transpharmation have formed a strategic partnership to align quantitative EEG endpoints between animal models and human clinical studies. This collaboration seeks to improve the high failure rate of central nervous system drug candidates moving from research to approval.
Why it matters
Only about 6.7% of central nervous system drug candidates currently reach FDA approval, in part due to a mismatch between preclinical testing and human outcomes. By harmonizing data collection across these stages, researchers hope to improve the selection of promising treatments for conditions like Alzheimer’s.
A cross-species analysis presented in February 2026 identified a conserved ketamine EEG signature in mice, rats, dogs, and humans, providing a potential bridge for drug testing. This preliminary research utilized the NeuLogiq Platform, which uses an FDA 510(k)-cleared wireless dry-EEG headset.
The players
Cumulus Neuroscience
A Belfast-based company developing decentralized clinical trial tools to accelerate drug discovery for neurodegenerative conditions.
Transpharmation
A London-based research organization specializing in preclinical models that bridge the gap to human pharmacology.
The details
The collaboration uses the NeuLogiq Platform, which combines a wireless dry-EEG headset with gamified, tablet-based assessments to capture neural activity in both the clinic and the home. By using these same EEG metrics in animal models and human trials, the partners aim to create a common language for drug efficacy. Transpharmation contributes expertise by benchmarking 26 specific physiological endpoints against established clinical gold standards, helping sponsors better predict how a candidate might perform in humans.
Timeline
February 2026: Researchers presented findings on cross-species EEG signatures in New Orleans.
October 14, 2026: Cumulus Neuroscience and Transpharmation announced their strategic partnership.
Health Landscape
Developing treatments for Alzheimer’s and other CNS disorders has historically been hampered by a lack of translatable biomarkers between preclinical and human studies. This partnership integrates the NeuLogiq Platform into a formal research pipeline to address these long-standing translational hurdles.
This development represents a behind-the-scenes shift in how new medicines are brought to market rather than a direct change to your current care. You can discuss with your physician how research into novel biomarkers and standardized clinical trial endpoints may shape the pipeline of future therapies.
The takeaway
Standardizing how researchers measure brain activity from early labs to human trials could significantly improve the success rate of new brain-health drugs. Patients should follow updates on clinical trial design, as improved measurement tools may help speed the arrival of more effective treatments.
Further reading
Find more context on emerging research and clinical trial methodologies in our Alzheimer’s section.
More information
Learn more about the technology behind this research by visiting the Cumulus Neuroscience company information portal.
Source note: This article includes information reported by Chatham Daily News.
Live Poll
Do you trust that strategic partnerships between research firms improve new medical treatment outcomes?
